Triaziquone

Triaziquone

SCHEMBL887253

CNCO.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DNMT1 P26358 1/20 0.38
NSD2 O96028 3/20 0.34
TTR P02766 1/20 0.34
APAF1 O14727 2/20 0.32
TDP2 O95551 2/20 0.32
HKDC1 Q2TB90 2/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL503952 0.98 TP53 (0.38) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL10720448 0.91 TP53 (0.34) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL11350903 0.88 HTT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL8974524 0.88 MAPT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL7117809 0.88 MAPT (0.44) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL1546343 0.86 MAPT (0.41) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL6387848 0.86 MAPT (0.41) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL1157120 0.86 MAPT (0.36) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL7783197 0.86 MAPT (0.46) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL9865090 0.84 TP53 (0.36) MAPTHTTTP53STAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4656181-A1 GLP-1 COMPOSITIONS AND PREPARATION METHOD Galenicum Health S.L.U. (ES) 2025-12-03 EP claimed
EP-4387590-A2 PHARMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS Topas Therapeutics GmbH (DE) 2024-06-26 EP claimed
WO-2023021098-A2 PHARMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS TOPAS THERAPEUTICS GMBH (DE) 2023-02-23 WO claimed
EP-2516448-B1 AMINE SALTS OF CEFDINIR BILGIC MAHMUT (TR) 2015-04-15 EP claimed
WO-2005059534-A1 REFILLABLE MICROPROBE JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2005-06-30 WO claimed
EP-0861340-B1 PROCESS FOR BINDING FIBROUS WEB CAMELOT SUPERABSORBENTS LTD (CA) 2001-04-25 EP claimed
EP-0753142-B1 System for gel electrophoresis NOVEX (US) 1999-08-11 EP claimed
EP-0585804-B1 Corn remover containing NaOH SALTRATES INTERNATIONAL S A (CH) 1998-10-14 EP claimed
US-5597560-A NON-STEROID ANTIINFLAMMATORY AGENT AND ANTIBIOTIC MIXTURE; SHELF LIFE LABORATORIOS CUSI, S.A. (ES) 1997-01-28 US claimed
EP-0523046-A1 2-ANILINO PHENYLACETIC ACID DERIVATIVES AS INHIBITORS OF PLA 2? AND LIPOXYGENASE AMERICAN HOME PRODUCTS CORPORATION (US) 1993-01-20 EP claimed
WO-1991006539-A1 2-ANILINO PHENYLACETIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE AMERICAN HOME PRODUCTS CORPORATION (US) 1991-05-16 WO claimed
EP-0417501-A1 Extra mild shower gel and hair-shampoo formulation with low surfactant concentration Joh. A. Benckiser GmbH (DE) 1991-03-20 EP claimed
EP-0049475-B1 SOLUBLE STABILIZED ENZYMES Modrovich, Ivan Endre (US) 1986-11-05 EP claimed
EP-0094366-B1 THERMAL ENERGY STORAGE SYSTEM Monsanto Company (US) 1986-05-28 EP claimed
EP-0034213-B1 A STABILIZED AQUEOUS COENZYME SOLUTION FOR USE IN A CLINICAL ASSAY, A METHOD OF STABILIZING A LABILE COENZYME IN AN AQUEOUS CLINICAL ASSAY SOLUTION AND A KIT FOR USE IN SAID CLINICAL ASSAY Modrovich, Ivan Endre (US) 1984-11-07 EP claimed
EP-0034778-B1 HETERO-IMINO-PROSTACYCLINS AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1984-04-25 EP claimed
US-20260000783-A1 ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW SAPREME TECHNOLOGIES B.V. (NL) 2026-01-01 US disclosed
EP-4656181-A1 GLP-1 COMPOSITIONS AND PREPARATION METHOD Galenicum Health S.L.U. (ES) 2025-12-03 EP disclosed
EP-0029893-A2 Process for concentration of tumor-inhibiting substances Theurer, Karl, Prof. Dr. (DE) 1981-06-10 EP disclosed
US-4083957-A SEPARATION OF SPERM, ELECTROSTATICS LANG JOHN L 1978-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000783-A1 ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW EPCAM, CD47, FCGR3B MAPT 3753/4885HTT 4725/4885TP53 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.